BioMarin Pharmaceutical Gelecekteki Büyüme

Future kriter kontrolleri 3/6

BioMarin Pharmaceutical kazanç ve gelirin sırasıyla yıllık 27.3% ve 7.7% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 26% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 11.9% olacağı tahmin edilmektedir.

Anahtar bilgiler

27.3%

Kazanç büyüme oranı

26.0%

EPS büyüme oranı

Biotechs kazanç büyümesi	28.3%
Gelir büyüme oranı	7.7%
Gelecekteki özkaynak getirisi	11.9%
Analist kapsamı	Good
Son güncelleme	21 Nov 2024

Gelecekteki son büyüme güncellemeleri

Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Apr 26

Recent updates

An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 46% Undervalued

Jun 01

BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain

May 15

Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Apr 26

BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shares Lagging The Industry But So Is The Business

Apr 21

Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?

Mar 30

BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth

Feb 29

BioMarin's Growth Potential And Valuation: Is Now The Right Time To Invest?

Jan 19

Little Excitement Around BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Revenues

Jan 05

Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 49% Discount?

Dec 15

Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?

Nov 03

Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 42% Discount?

Aug 09

We Think BioMarin Pharmaceutical (NASDAQ:BMRN) Can Stay On Top Of Its Debt

Jul 18

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Could Be 42% Below Their Intrinsic Value Estimate

May 09

Why Investors Shouldn't Be Surprised By BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Low P/S

Apr 18

These 4 Measures Indicate That BioMarin Pharmaceutical (NASDAQ:BMRN) Is Using Debt Safely

Mar 27

An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 39% Undervalued

Jan 09

BioMarin redesigns organization, will lay off about 4% of its workforce

Oct 07

BioMarin resubmits biologics license application to FDA for hemophilia A gene therapy

Sep 29

BioMarin touts report on cost effectiveness of gene therapy Roctavian for hemophilia A

Sep 15

BioMarin to resubmit hemophilia therapy for FDA approval after EU nod

Aug 25

BioMarin may be an activist target after 13-F filings

Aug 15

BioMarin (BMRN) boosts 2022 top and bottom line guidance on back of product sales growth

Aug 03

BioMarin: More Growth

Jul 21

BioMarin's Solid Pipeline Bears The First Fruit

Jun 27

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:BMRN - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	3,403	792	962	937	23
12/31/2025	3,102	583	794	823	28
12/31/2024	2,815	398	657	607	29
9/30/2024	2,753	322	311	415	N/A
6/30/2024	2,588	257	223	329	N/A
3/31/2024	2,472	205	173	280	N/A
12/31/2023	2,419	168	52	159	N/A
9/30/2023	2,311	147	25	139	N/A
6/30/2023	2,235	100	34	161	N/A
3/31/2023	2,173	72	15	147	N/A
12/31/2022	2,096	142	148	176	N/A
9/30/2022	2,008	84	151	180	N/A
6/30/2022	1,912	54	106	119	N/A
3/31/2022	1,880	39	134	146	N/A
12/31/2021	1,846	-64	185	305	N/A
9/30/2021	1,849	16	165	280	N/A
6/30/2021	1,917	837	155	269	N/A
3/31/2021	1,844	795	92	214	N/A
12/31/2020	1,860	854	15	85	N/A
9/30/2020	1,863	852	75	156	N/A
6/30/2020	1,847	122	58	140	N/A
3/31/2020	1,805	114	3	88	N/A
12/31/2019	1,704	-24	-90	48	N/A
9/30/2019	1,603	-43	-59	40	N/A
6/30/2019	1,533	-110	-112	17	N/A
3/31/2019	1,519	-90	-87	8	N/A
12/31/2018	1,491	-77	-74	20	N/A
9/30/2018	1,496	-125	-12	-15	N/A
6/30/2018	1,439	-125	N/A	-23	N/A
3/31/2018	1,383	-145	N/A	29	N/A
12/31/2017	1,314	-117	N/A	-9	N/A
9/30/2017	1,255	-156	N/A	-24	N/A
6/30/2017	1,201	-181	N/A	-72	N/A
3/31/2017	1,184	-563	N/A	-137	N/A
12/31/2016	1,117	-630	N/A	-228	N/A
9/30/2016	1,045	-471	N/A	-293	N/A
6/30/2016	974	-524	N/A	-286	N/A
3/31/2016	924	-187	N/A	-253	N/A
12/31/2015	890	-172	N/A	-219	N/A
9/30/2015	892	-310	N/A	-179	N/A
6/30/2015	859	-212	N/A	-185	N/A
3/31/2015	801	-163	N/A	-183	N/A
12/31/2014	749	-134	N/A	-70	N/A
9/30/2014	666	-126	N/A	-58	N/A
6/30/2014	627	-187	N/A	-59	N/A
3/31/2014	572	-175	N/A	-54	N/A
12/31/2013	548	-176	N/A	-57	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: BMRN 'nin tahmini kazanç büyümesi (yıllık 27.3% ) tasarruf oranının ( 2.6% ) üzerindedir.

Kazançlar ve Piyasa: BMRN şirketinin kazançlarının (yıllık 27.3% ) US pazarından (yıllık 15.4% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: BMRN şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: BMRN şirketinin gelirinin (yıllık 7.7% ) US pazarından (yıllık 8.9% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: BMRN şirketinin gelirinin (yıllık 7.7% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: BMRN 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 11.9 %).

BioMarin Pharmaceutical Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Biomarin Pharmaceutical Inc. Revises Earnings Guidance for the Full Year 2024

Price target decreased by 7.0% to US$104

Biomarin Pharmaceutical Inc. Provides Earnings Guidance for the Full Year 2024 and for Fiscal Year 2027

Consensus EPS estimates increase by 10%

Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Consensus EPS estimates increase by 17%

Recent updates

Biomarin: Challanges Mount, But Sale Rumours Make For A Risky "Buy" Call

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Not Flying Under The Radar

New minor risk - Earnings quality

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Biomarin Pharmaceutical Inc. Revises Earnings Guidance for the Full Year 2024

Price target decreased by 7.0% to US$104

BioMarin Pharmaceutical (NASDAQ:BMRN) Seems To Use Debt Rather Sparingly

BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia At 2024 International Skeletal Dysplasia Society Meeting

Investor sentiment deteriorates as stock falls 17%

Biomarin Pharmaceutical Inc. Provides Earnings Guidance for the Full Year 2024 and for Fiscal Year 2027

BioMarin: Voxzogo Sales Surge Isn't Only Driving Force In 2024

BioMarin Pharmaceutical Inc. Announces Management Changes

Consensus EPS estimates increase by 10%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease

BioMarin Pharmaceutical: Steady Performer Scheduling Its Big Reveal In 09/2024

BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) dropped from Russell Small Cap Comp Growth Index

An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 46% Undervalued

Executive VP notifies of intention to sell stock

BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain

Director notifies of intention to sell stock

Biomarin Pharmaceutical Inc. Announces Positive New Data Supporting the Safety and Efficacy of VOXZOGO® (Vosoritide) in Children

Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

First quarter 2024 earnings: EPS exceeds analyst expectations

Consensus EPS estimates increase by 17%

BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shares Lagging The Industry But So Is The Business

Director notifies of intention to sell stock

BioMarin Pharmaceutical Inc., Annual General Meeting, May 21, 2024

Executive VP notifies of intention to sell stock

Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?

Insider recently sold US$3.0m worth of stock

Insider notifies of intention to sell stock

Biomarin Announces Board Changes, Effective May 20, 2024

BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth

Full year 2023 earnings released: EPS: US$0.89 (vs US$0.76 in FY 2022)

BioMarin Pharmaceutical Inc. Provides Earnings Guidance for the Year 2024

Director notifies of intention to sell stock

BioMarin's Growth Potential And Valuation: Is Now The Right Time To Invest?

Biomarin Pharmaceutical Inc. Announces Resignation of Jeffrey Ajer as Executive Vice President and Chief Commercial Officer, Effective from July 1, 2024

Director notifies of intention to sell stock

Little Excitement Around BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Revenues

Director notifies of intention to sell stock

BioMarin Pharmaceutical Inc. Announces Board Appointments, Effective December 27, 2023

Executive VP notifies of intention to sell stock

Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 49% Discount?

Biomarin Pharmaceutical Inc. Announces CEO Changes

Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

BioMarin Pharmaceutical Inc. Revises Financial Guidance for the Full Year 2023

U.S. Food and Drug Administration Approves Biomarin's Voxzogo® (Vosoritide) for Children Under 5 Years with Achondroplasia

Biomarin Pharmaceutical Inc. to Present Data Showing Long-Term Benefit of Vosoritide on Growth in Children with Achondroplasia At 2023 European Society for Paediatric Endocrinology Meeting

BioMarin Pharmaceutical Inc. Announces First Person Treated with ROCTAVIAN (Valoctocogene Rxaparvovec-Rvox) for Severe Hemophilia A in Europe

Executive VP recently sold US$984k worth of stock

Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 42% Discount?

Second quarter 2023 earnings: EPS exceeds analyst expectations

Biomarin Pharmaceutical Inc. Updates Earnings Guidance for the Year Ended December 31, 2023

We Think BioMarin Pharmaceutical (NASDAQ:BMRN) Can Stay On Top Of Its Debt

Bernstein Litowitz Berger & Grossmann LLP Announces Pendency of Class Action and Proposed Settlement for Purchasers of Biomarin Pharmaceutical Inc

U.S. Food and Drug Administration Approves Biomarin's Roctavian® (Valoctocogene Rxaparvovec-Rvox) Gene Therapy for Adults with Severe Hemophilia A

BioMarin Pharmaceutical Inc. to Present Roctavian™ Data from Longest and Largest Hemophilia Gene Therapy Clinical Trial Program

Chairman & CEO notifies of intention to sell stock

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Could Be 42% Below Their Intrinsic Value Estimate

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 13%

Why Investors Shouldn't Be Surprised By BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Low P/S

Independent Director notifies of intention to sell stock

These 4 Measures Indicate That BioMarin Pharmaceutical (NASDAQ:BMRN) Is Using Debt Safely

Chairman & CEO notifies of intention to sell stock

Executive VP & Chief Legal Officer exercised options to buy US$148k worth of stock.